{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:53:06Z","timestamp":1790358786123,"version":"4.1.0"},"reference-count":52,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T00:00:00Z","timestamp":1493856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009082","name":"Universidad Cat\u00f3lica de C\u00f3rdoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002911","name":"Universidad Complutense de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002911","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:p>The main objectives of this study were (i) to evaluate the serum pharmacokinetic behaviour and milk penetration of marbofloxacin (MFX; 5\u00a0mg\/kg), after intravenous (<jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content>) and intramuscular (<jats:styled-content style=\"fixed-case\">IM<\/jats:styled-content>) administration in lactating goats and simulate a multidose regimen on steady\u2010state conditions, (ii) to determine the minimum inhibitory concentration (<jats:styled-content style=\"fixed-case\">MIC<\/jats:styled-content>) and mutant prevention concentration (<jats:styled-content style=\"fixed-case\">MPC<\/jats:styled-content>) of coagulase negative staphylococci (<jats:styled-content style=\"fixed-case\">CNS<\/jats:styled-content>) isolated from caprine mastitis in C\u00f3rdoba, Argentina and (iii) to make a <jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content> analysis by Monte Carlo simulation from steady\u2010state pharmacokinetic parameters of <jats:styled-content style=\"fixed-case\">MFX<\/jats:styled-content> by <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">IM<\/jats:styled-content> routes to evaluate the efficacy and risk of the emergence of resistance. The study was carried out with six healthy, female, adult Anglo Nubian lactating goats. Marbofloxacin was administered at 5\u00a0mg\/kg bw by <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">IM<\/jats:styled-content> route. Serum and milk concentrations of MFX were determined with <jats:styled-content style=\"fixed-case\">HPLC<\/jats:styled-content>\/uv. From 106 regional strains of <jats:styled-content style=\"fixed-case\">CNS<\/jats:styled-content> isolated from caprine mastitis in herds from C\u00f3rdoba, Argentina, <jats:styled-content style=\"fixed-case\">MIC<\/jats:styled-content>s and <jats:styled-content style=\"fixed-case\">MPC<\/jats:styled-content>s were determined. <jats:styled-content style=\"fixed-case\">MIC<\/jats:styled-content><jats:sub>90<\/jats:sub> and <jats:styled-content style=\"fixed-case\">MPC<\/jats:styled-content><jats:sub>90<\/jats:sub> were 0.4 and 6.4\u00a0\u03bcg\/ml, respectively. <jats:styled-content style=\"fixed-case\">MIC<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">MPC<\/jats:styled-content>\u2010based <jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content> analysis by Monte Carlo simulation indicates that <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">IM<\/jats:styled-content> administration of <jats:styled-content style=\"fixed-case\">MFX<\/jats:styled-content> in lactating goats may not be adequate to recommend it as an empirical therapy against <jats:styled-content style=\"fixed-case\">CNS<\/jats:styled-content>, because the most exigent endpoints were not reached. Moreover, this dose regimen could increase the probability of selecting mutants and resulting in emergence of resistance. Based on the results of Monte Carlo simulation, the optimal dose of <jats:styled-content style=\"fixed-case\">MFX<\/jats:styled-content> to achieve an adequate antimicrobial efficacy should be 10\u00a0mg\/kg, but it is important take into account that fluoroquinolones are substrates of efflux pumps, and this fact may determine that assumption of linear pharmacokinetics at high doses of <jats:styled-content style=\"fixed-case\">MFX<\/jats:styled-content> may be incorrect.<\/jats:p>","DOI":"10.1111\/jvp.12409","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T07:32:40Z","timestamp":1493883160000},"page":"629-640","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacokinetics, milk penetration and <scp>PK<\/scp>\/<scp>PD<\/scp> analysis by Monte Carlo simulation of marbofloxacin, after intravenous and intramuscular administration to lactating goats"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9799-4499","authenticated-orcid":false,"given":"A. M.","family":"Lorenzutti","sequence":"first","affiliation":[{"name":"Facultad de Ciencias Agropecuarias\u2010Unidad Asociada al CONICET Universidad Cat\u00f3lica de C\u00f3rdoba  C\u00f3rdoba Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. J.","family":"Litterio","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias Agropecuarias\u2010Unidad Asociada al CONICET Universidad Cat\u00f3lica de C\u00f3rdoba  C\u00f3rdoba Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Himelfarb","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias Agropecuarias\u2010Unidad Asociada al CONICET Universidad Cat\u00f3lica de C\u00f3rdoba  C\u00f3rdoba Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. d. P.","family":"Zarazaga","sequence":"additional","affiliation":[{"name":"Facultad de Ciencias Agropecuarias\u2010Unidad Asociada al CONICET Universidad Cat\u00f3lica de C\u00f3rdoba  C\u00f3rdoba Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. I.","family":"San Andr\u00e9s","sequence":"additional","affiliation":[{"name":"Departamento de Toxicolog\u00eda y Farmacolog\u00eda Facultad de Veterinaria Universidad Complutense de Madrid  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"De Lucas","sequence":"additional","affiliation":[{"name":"Departamento de Toxicolog\u00eda y Farmacolog\u00eda Facultad de Veterinaria Universidad Complutense de Madrid  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,5,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020243615928"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.2001.62.1979"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.03.011"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(00)00185-1"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.10.2793-2797.2001"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2015.02.001"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2012.01038.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1051\/vetres:2003030"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2013.04.023"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.00759"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2007.11.025"},{"key":"e_1_2_6_13_1","volume-title":"Performance standards for antimicrobial susceptibility testing; twenty\u2010third informational supplement. CLSI document M100\u2010S23","author":"CLSI","year":"2013"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smallrumres.2006.09.011"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2581-2584.2000"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1086\/518137"},{"key":"e_1_2_6_17_1","unstructured":"EMEA. (2000).EMEA\/MRL\/693\/99\u2010FINAL. Marbofloxacin Summary Report\u00a0(2).http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Maximum_Residue_Limits_-_Report\/2009\/11\/WC500014865.pdf. Consulted: 20 July 2016."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2007.00898.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.3168\/jds.S0022-0302(96)76336-1"},{"key":"e_1_2_6_20_1","volume-title":"Estudio farmacocin\u00e9tico de formulaciones polim\u00e9ricas de liberaci\u00f3n controlada para Marbofloxacino en caprino","author":"Fern\u00e1ndez\u2010Palacios R.","year":"2013"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2005.04.017"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00156-07"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00578-13"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1604-1613.2003"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.028654-0"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2011.07.033"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2008.01001.x"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0034-5288(03)00003-1"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01372-06"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2011.01361.x"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00975-10"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.69-74.2002"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0450.1992.tb01166.x"},{"key":"e_1_2_6_34_1","first-page":"74","article-title":"Pharmacokinetics and milk penetration of ibafloxacin after intravenous administration to lactating goats","volume":"71","author":"Mar\u00edn P.","year":"2007","journal-title":"The Canadian Journal of Veterinary Research"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.3168\/jds.2007-0071"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2007.00818.x"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2003.12.011"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2013.12.021"},{"key":"e_1_2_6_39_1","first-page":"983","volume-title":"Veterinary Pharmacology and Therapeutics","author":"Papich M. G.","year":"2009"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0442.1997.tb01137.x"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2885.1998.00137.x"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/1751-0147-55-37"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2009.02.009"},{"key":"e_1_2_6_44_1","first-page":"44","article-title":"Effect of induced mastitis on disposition kinetics of gatifloxacin following intravenous administration in goats","volume":"2","author":"Singh V.","year":"2010","journal-title":"Journal of Bioanalaysis and Biomedicine"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.03.013"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0034-5288(02)00039-5"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2006.01.059"},{"key":"e_1_2_6_48_1","unstructured":"USP. (2007).United States Pharmacopeia Convention. Fluoroquinolones (Veterinary\u2014Systemic). Retrieved fromhttp:\/\/c.ymcdn.com\/sites\/www.aavpt.org\/resource\/resmgr\/imported\/fluoroquinolones.pdf. Consulted: 24 July 2016."},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2885.2001.00357.x"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2885.2003.00462.x"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2004.00548.x"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2006.05.004"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.10.4166-4173.2005"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvp.12409","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvp.12409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T04:50:09Z","timestamp":1695963009000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvp.12409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,4]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/jvp.12409"],"URL":"https:\/\/doi.org\/10.1111\/jvp.12409","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,4]]}}}